Burres N S, Clement J J
Division of Biomedical Marine Research, Harbor Branch Oceanographic Institution, Inc., Ft. Pierce, Florida 34946.
Cancer Res. 1989 Jun 1;49(11):2935-40.
Three novel heterocyclic compounds, mycalamide-A and -B and onnamide, were isolated from Mycale sp. and Theonella sp. sponges collected in New Zealand and Okinawan waters. Each exhibited potent in vitro toxicity and in vivo efficacy against murine and human tumor cells. Concentrations of each that inhibited replication of cultured murine lymphoma P388 cells by 50% were 5 nM or less. Mycalamide-A and -B were also potent inhibitors of HL-60, HT-29, and A549 human tumor cell replication (50% inhibitory concentration less than 5 nM), while values for onnamide were greater (50% inhibitory concentrations between 25 and 200 nM). Mycalamide-A (10 micrograms/kg) and -B (2.5 micrograms/kg) were moderately active against P388 leukemia (increase in life span, approximately 50%), while onnamide was inactive (40 micrograms/kg; increase in life span, 15%). Mycalamide-A was also active against B16 melanoma, Lewis lung carcinoma, M5076 ovarian sarcoma, colon 26 carcinoma, and the human MX-1, CX-1, and Burkitt's lymphoma tumor xenografts. Mechanism of action studies indicate that the three agents inhibited protein synthesis. For example, after 1-h exposures to 20 nM mycalamide-A and -B, the rates of [3H]leucine incorporation into acid-precipitable material of cultured P388 cells were inhibited 54 and 99%, while the effects on incorporation of [3H]uridine and [3H]thymidine were less. The relative effects of 20 to 2000 nM mycalamide-A on protein, RNA, and DNA synthesis were consistent with those observed during exposure of P388 cells to 1 microM emetine, a known inhibitor of protein synthesis. Also, the three agents inhibited translation of RNA into protein in a cell-free lysate of rabbit reticulocytes. Although mycalamide-A disrupted DNA metabolism, the agent apparently did not intercalate into DNA, and a mixture of four deoxynucleosides (250 microM each) did not decrease the antiproliferative effects of the agent. Collectively, these data indicate that this class of compounds represents novel antitumor agents which should be further evaluated to define their potential.
从新西兰和冲绳海域采集的Mycale属和Theonella属海绵中分离出三种新型杂环化合物,即肉芝软海绵酸-A、肉芝软海绵酸-B和瘤孢酰胺。每种化合物对鼠类和人类肿瘤细胞均表现出强大的体外毒性和体内疗效。抑制培养的鼠淋巴瘤P388细胞复制50%所需的每种化合物浓度均为5 nM或更低。肉芝软海绵酸-A和肉芝软海绵酸-B也是HL-60、HT-29和A549人类肿瘤细胞复制的有效抑制剂(半数抑制浓度小于5 nM),而瘤孢酰胺的半数抑制浓度更高(25至200 nM)。肉芝软海绵酸-A(10微克/千克)和肉芝软海绵酸-B(2.5微克/千克)对P388白血病具有中等活性(寿命延长约50%),而瘤孢酰胺则无活性(40微克/千克;寿命延长15%)。肉芝软海绵酸-A对B16黑色素瘤、Lewis肺癌、M5076卵巢肉瘤、结肠26癌以及人类MX-1、CX-1和伯基特淋巴瘤肿瘤异种移植也有活性。作用机制研究表明,这三种药物均抑制蛋白质合成。例如,在将培养的P388细胞暴露于20 nM肉芝软海绵酸-A和肉芝软海绵酸-B 1小时后,[3H]亮氨酸掺入酸性可沉淀物质的速率分别被抑制54%和99%,而对[3H]尿苷和[3H]胸苷掺入的影响较小。20至2000 nM肉芝软海绵酸-A对蛋白质、RNA和DNA合成的相对影响与P388细胞暴露于1 microM依米丁(一种已知的蛋白质合成抑制剂)期间观察到的结果一致。此外,这三种药物在兔网织红细胞的无细胞裂解物中均抑制RNA翻译成蛋白质。尽管肉芝软海绵酸-A破坏了DNA代谢,但该药物显然未插入DNA中,并且四种脱氧核苷的混合物(每种250 microM)并未降低该药物的抗增殖作用。总体而言,这些数据表明这类化合物代表新型抗肿瘤药物,应进一步评估以确定其潜力。